Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus platinum-doublet chemotherapy for resectable stage II-III non-small cell lung cancer
CTR20202441Phase 3Completed
- Sponsor
- Suzhou Union Biopharm
- Start
- Apr 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in non-small cell lung cancer (NSCLC), sponsored by Suzhou Union Biopharm. Started Apr 2020; status: completed.
02
Drugs
toripalimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20202441.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202441.